The IL13α 2R paves the way for anti-glioma nanotherapy

Ilya V. Ulasov; Anton Borovjagin; Anastasia Laevskaya; Margarita Kamynina; Peter Timashev; Laura Cerchia; Elena A. Rozhkova

doi:10.1016/j.gendis.2021.08.006

您当前的位置：

首页 >

文章列表页 >

The IL13α 2R paves the way for anti-glioma nanotherapy

Review article | 更新时间：2023-08-29

- The IL13α 2R paves the way for anti-glioma nanotherapy
- The IL13α 2R paves the way for anti-glioma nanotherapy
- Genes & Diseases 2023年10卷第1期
- 作者机构：
  
  1. Group of Experimental Biotherapy and Diagnostic, Institute for Regenerative Medicine, World-Class Research Center “Digital Biodesign and Personalized Healthcare”, Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St.,Moscow,Russia,119991
  2. Department of BioMedical Engineering, University of Alabama at Birmingham,AL,Birmingham,USA,35294
  3. Institute for Regenerative Medicine, World-Class Research Center “Digital Biodesign and Personalized Healthcare”, Sechenov First Moscow State Medical University (Sechenov University), 8-2 Trubetskaya St.,Moscow,Russia,119991
  4. Department of Polymers and Composites, N.N. Semenov Institute of Chemical Physics, 4 Kosygin St,Moscow,Russia,119991
  5. Chemistry Department, Lomonosov Moscow State University, Leninskiye Gory 1-3,Moscow,Russia,119991
  6. Institute of Experimental Endocrinology and Oncology “G. Salvatore” (IEOS), National Research Council (CNR),Naples,Italy,80131
  7. Center for Nanoscale Materials, Argonne National Laboratory, Argonne,IL,USA,60439
- 作者简介：
- 基金信息：
- DOI：10.1016/j.gendis.2021.08.006
  中图分类号：
- 纸质出版日期：2023，
  
  网络出版日期：2023-1-1，
扫描看全文
Ilya V. Ulasov, Anton Borovjagin, Anastasia Laevskaya, 等. The IL13α 2R paves the way for anti-glioma nanotherapy[J]. Genes & Diseases, 2023,10(1).

Ilya V. Ulasov, Anton Borovjagin, Anastasia Laevskaya, et al. The IL13α 2R paves the way for anti-glioma nanotherapy[J]. Genes & Diseases, 2023,10(1).
Ilya V. Ulasov, Anton Borovjagin, Anastasia Laevskaya, 等. The IL13α 2R paves the way for anti-glioma nanotherapy[J]. Genes & Diseases, 2023,10(1). DOI： 10.1016/j.gendis.2021.08.006.

Ilya V. Ulasov, Anton Borovjagin, Anastasia Laevskaya, et al. The IL13α 2R paves the way for anti-glioma nanotherapy[J]. Genes & Diseases, 2023,10(1). DOI： 10.1016/j.gendis.2021.08.006.

摘要

Abstract

Glioblastoma (GBM) is one of the most aggressive (grade IV) gliomas characterized by a high rate of recurrence

resistance to therapy and a grim survival prognosis. The long-awaited improvement in GBM patients’ survival rates essentially depends on advances in the development of new therapeutic approaches. Recent preclinical studies show that nanoscale materials could greatly contribute to the improvement of diagnosis and management of brain cancers. In the current review

we will discuss how specific features of glioma pathobiology can be employed for designing efficient targeting approaches. Moreover

we will summarize the main evidence for the potential of the IL-13R alpha 2 receptor (IL13α2R) targeting in GBM early diagnosis and experimental therapy.

关键词

Keywords

Brain tumorExperimental therapyGBMIL-13Rα2NanoparticlesReceptorViral vectors

references

查看原文

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

Clinical applications of the CRISPR/Cas9 genome-editing system: Delivery options and challenges in precision medicine